Back to Search Start Over

A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma.

Authors :
MacFarlane J
Seong KC
Bisambar C
Madhu B
Allinson K
Marker A
Warren A
Park SM
Giger O
Challis BG
Maher ER
Casey RT
Source :
Clinical endocrinology [Clin Endocrinol (Oxf)] 2020 Nov; Vol. 93 (5), pp. 528-538. Date of Electronic Publication: 2020 Aug 14.
Publication Year :
2020

Abstract

The citric acid cycle, also known as the Krebs cycle, plays an integral role in cellular metabolism and aerobic respiration. Mutations in genes encoding the citric acid cycle enzymes succinate dehydrogenase, fumarate hydratase and malate dehydrogenase all predispose to hereditary tumour syndromes. The succinate dehydrogenase enzyme complex (SDH) couples the oxidation of succinate to fumarate in the citric acid cycle and the reduction of ubiquinone to ubiquinol in the electron transport chain. A loss of function in the succinate dehydrogenase (SDH) enzyme complex is most commonly caused by an inherited mutation in one of the four SDHx genes (SDHA, SDHB, SDHC and SDHD). This mechanism was first implicated in familial phaeochromocytoma and paraganglioma. However, over the past two decades the spectrum of tumours associated with SDH deficiency has been extended to include gastrointestinal stromal tumours (GIST), renal cell carcinoma (RCC) and pituitary adenomas. The aim of this review is to describe the extended tumour spectrum associated with SDHx gene mutations and to consider how functional tests may help to establish the role of SDHx mutations in new or unexpected tumour phenotypes.<br /> (© 2020 John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2265
Volume :
93
Issue :
5
Database :
MEDLINE
Journal :
Clinical endocrinology
Publication Type :
Academic Journal
Accession number :
32686200
Full Text :
https://doi.org/10.1111/cen.14289